Immunovant (IMVT) Competitors

In the previous week, Insmed had 15 more articles in the media than Immunovant. MarketBeat recorded 24 mentions for Insmed and 9 mentions for Immunovant. Insmed's average media sentiment score of 0.92 beat Immunovant's score of 0.14 indicating that Insmed is being referred to more favorably in the media.

Immunovant has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

47.1% of Immunovant shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 1.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Insmed currently has a consensus target price of $205.26, suggesting a potential upside of 56.86%. Immunovant has a consensus target price of $44.00, suggesting a potential upside of 11.79%. Given Insmed's stronger consensus rating and higher possible upside, research analysts plainly believe Insmed is more favorable than Immunovant.

Immunovant has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Immunovant's return on equity of -65.66% beat Insmed's return on equity.

Insmed has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

47.1% of Immunovant shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 1.9% of Immunovant shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Immunovant has higher earnings, but lower revenue than BioNTech. Immunovant is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Immunovant's return on equity.

Immunovant has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

Immunovant currently has a consensus price target of $44.00, suggesting a potential upside of 11.79%. BioNTech has a consensus price target of $127.81, suggesting a potential upside of 36.73%. Given BioNTech's stronger consensus rating and higher probable upside, analysts plainly believe BioNTech is more favorable than Immunovant.

In the previous week, BioNTech had 15 more articles in the media than Immunovant. MarketBeat recorded 24 mentions for BioNTech and 9 mentions for Immunovant. Immunovant's average media sentiment score of 0.14 beat BioNTech's score of -0.17 indicating that Immunovant is being referred to more favorably in the media.

Immunovant has higher earnings, but lower revenue than Moderna. Immunovant is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Immunovant has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

In the previous week, Moderna had 58 more articles in the media than Immunovant. MarketBeat recorded 67 mentions for Moderna and 9 mentions for Immunovant. Moderna's average media sentiment score of 0.43 beat Immunovant's score of 0.14 indicating that Moderna is being referred to more favorably in the news media.

47.1% of Immunovant shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 1.9% of Immunovant shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immunovant presently has a consensus price target of $44.00, indicating a potential upside of 11.79%. Moderna has a consensus price target of $42.13, indicating a potential downside of 27.94%. Given Immunovant's stronger consensus rating and higher possible upside, analysts clearly believe Immunovant is more favorable than Moderna.

Immunovant has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Immunovant's return on equity.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immunovant has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Immunovant currently has a consensus target price of $44.00, indicating a potential upside of 11.79%. Viatris has a consensus target price of $17.50, indicating a potential upside of 5.77%. Given Immunovant's higher possible upside, analysts clearly believe Immunovant is more favorable than Viatris.

In the previous week, Viatris had 6 more articles in the media than Immunovant. MarketBeat recorded 15 mentions for Viatris and 9 mentions for Immunovant. Viatris' average media sentiment score of 0.56 beat Immunovant's score of 0.14 indicating that Viatris is being referred to more favorably in the news media.

Immunovant has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Immunovant has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Immunovant's return on equity.